US 7901671B2
· Leboulch et al.
· 2011
[cited by applicant]
US 9994867B2
· Baltimore et al.
· 2018
[cited by applicant]
US 20150182617A1
· Bauche et al.
· 2015
[cited by applicant]
US 20170176435A1
· Seidell, III et al.
· 2017
[cited by applicant]
US 20170240631A1
· Monroe et al.
· 2017
[cited by applicant]
US 20190161530A1
· Certo et al.
· 2019
[cited by applicant]
US 20210128619A1
· Campbell
· 2021
[cited by examiner]
US 20210137977A1
· Chaudhary
· 2021
[cited by applicant]
US 20220204946A1
· Antunes et al.
· 2022
[cited by applicant]
US 20220340876A1
· Birnbaum et al.
· 2022
[cited by applicant]
US 20230167158A1
· Najjar et al.
· 2023
[cited by applicant]
US 20240218390A1
· Perkins et al.
· 2024
[cited by applicant]
US 20250101106A1
· Friedman et al.
· 2025
[cited by applicant]
US 20250101122A1
· Friedman et al.
· 2025
[cited by applicant]
CA 2344208A1
· 2002
[cited by applicant]
CN 1643164A
· 2005
[cited by applicant]
CN 108040484A
· 2018
[cited by applicant]
CN 115322257A
· 2022
[cited by applicant]
EP 2020444A1
· 2009
[cited by applicant]
EP 1461079B1
· 2011
[cited by applicant]
JP 2005247757A
· 2005
[cited by applicant]
JP 2016501528A
· 2016
[cited by applicant]
WO 200119380A2
· 2001
[cited by applicant]
WO 2008037458A2
· 2008
[cited by applicant]
WO 2009013324A1
· 2009
[cited by applicant]
WO 2010040023A2
· 2010
[cited by applicant]
WO 2012088381A2
· 2012
[cited by applicant]
WO 2015104376A1
· 2015
[cited by applicant]
WO 2015112541A2
· 2015
[cited by applicant]
WO 2015117027A1
· 2015
[cited by applicant]
WO 2016139463A1
· 2016
[cited by applicant]
WO 2017182585A1
· 2017
[cited by applicant]
WO 2019056015A2
· 2019
[cited by applicant]
WO 2019057974A1
· 2019
[cited by applicant]
WO 2020123936A1
· 2020
[cited by applicant]
WO 2020236263A1
· 2020
[cited by applicant]
WO 2022013872A1
· 2022
[cited by applicant]
WO 2022183072A1
· 2022
[cited by applicant]
WO 2022221745A1
· 2022
[cited by applicant]
WO 2025038475A1
· 2025
[cited by applicant]
WO 2025072253A1
· 2025
[cited by applicant]
WO 2025072257A1
· 2025
[cited by applicant]
Mishra et al, CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond, Vaccines, 2023, pp. 1-23.
[cited by examiner]
Short et al, Direct in vivo CAR T cell engineering, Trends in Pharmacological Sciences, May 2024, pp. 406-418.
[cited by examiner]
Agarwal et al., In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes, Molecular Therapy, 2020, pp. 1783-1794.
[cited by examiner]
Pinto et al., From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy, . Journal of Translational Medicine, 2025, pp. 1-16.
[cited by examiner]
Winkler, K., et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody,” J Immunol, 165(8):4505-14 (2000).
[cited by applicant]
Yang, H., et al., “Cell Type-Specific Targeting with Surface-Engineered Lentiviral Vectors Co-displaying OKT3 Antibody and Fusogenic Molecule,” Pharm Res, 26(6): 1432-45 (2009).
[cited by applicant]
Yang, et al., “Targeting Lentiviral Vectors to Specific Cell Types in vivo,” PNAS, 103(31 ): 114 79-84 (2006).
[cited by applicant]
Yu, B., et al., “Engineered Cell Entry Links Receptor Biology with Single-cell Genomics,” Cell, 185(26): 4904-4920 (2022).
[cited by applicant]
Zhang, et al, “Cell-specific Targeting of Lentiviral Vectors Mediated by Fusion Proteins Derived from Sindbis Virus, Vesicular Stomatitis Virus, or Avian Sarcoma/Leukosis Virus,” Retrovirology, Biomed Central Ltd., 7(1)…
[cited by applicant]
Zhang, N., et al., “Leucine-rich Repeat-containing G Protein-coupled Receptor 4 Facilitates Vesicular Stomatitis Virus Infection by Binding Vesicular Stomatitis Virus Glycoprotein,” J Biol Chem, 292(40):16527-16538 (201…
[cited by applicant]
Albertini, et al., “Molecular and Cellular Aspects of Rhabdovirus Entry,” Viruses, 4:117-139 (2012).
[cited by applicant]
Altschul, et al., “Basic Local Alignment Search Tool,” J Mol Biol. (3):403-10 (1990).
[cited by applicant]
Altschul, et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucleic Acids Res, 25(17):3389-402 (1997).
[cited by applicant]
Amirache, et al., “Mystery Solved: VSV-G-LVs Do Not Allow Efficient Gene Transfer into Unstimulated T Cells, B Cells, and HSCs Because They Lack the LDL Receptor,” Blood, 123: 1422-1424 (2014).
[cited by applicant]
Ammayappan, et al., “Characteristics of Oncolytic Vesicular Stomatitis Virus Displaying Tumor-Targeting Ligands,” Journal of Virology vol. 87(24):13543-13555 (2013).
[cited by applicant]
An, X., “Preliminary Study on HBV and HIV seudovirus Vector Systems,” China Master's Thesis Full-text Database, Basic Science Collection: 1-121 (2007).
[cited by applicant]
Barber, G.N., “VSV-tumor Selective Replication and Protein Translation,” Oncogene 24: 7710-7719 (2005).
[cited by applicant]
Bentzen, et al., “Evolution of MHC-based Technologies Used for Detection of Antigen-responsive T Cells,” Cancer Immunol Immunother, 66:657-66 (2017).
[cited by applicant]
Bowie, J., et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 247(4948):1306-10 (1990).
[cited by applicant]
Buchholz, et al., “Retroviral Display and High Throughput Screening,” Comb Chem High Throughput Screen, 11(2):99-110 (2008).
[cited by applicant]
Chan, L., et al., “Conjugation of Lentivirus to Paramagnetic Particles via Nonviral Proteins Allows Efficient Concentration and Infection of Primary Acute Myeloid Leukemia Cells,” J. of Virology, 79(20):13190-13194 (200…
[cited by applicant]
Chen, Z., et al., “Human Monoclonal Antibodies Targeting the Haemagglutinin Glycoprotein can Neutralize H7N9 Influenza Virus,” Nat Commun, 6:6714 (2015).
[cited by applicant]
Cire, S, “Immunization of Mice with Lentiviral Vectors Targeted to MHC Class II+ Cells is Due to Preferential Transduction of Dendritic Cells in vivo,” PLoS One, 9(7):e101644, (2014).
[cited by applicant]
Dobson, C., et al., “Antigen Identification and High-Throughput Interaction Mapping by Reprogramming Viral Entry,” Nature Methods, 19:449-460 (2022).
[cited by applicant]
Dreja, H., et al., “The Effects of N-terminal Insertion into VSV-G of an scFv Peptide,” Viral J, 3:69, 1186 (2006).
[cited by applicant]
Ferlin, et al., “Characterization of pH-sensitive Molecular Switches that Trigger the Structural Transition of Vesicular Stomatitis Virus Glycoprotein from the Postfusion State Toward the Prefusion State,” J Virol, 88:1…
[cited by applicant]
Finkelshtein, et al., “LDL Receptor and its Family Members Serve as the Cellular Receptors for Vesicular Stomatitis Virus,” PNAS, 110(18):7306-7311 (2013).
[cited by applicant]
Frank, A., et al., “Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes,” Mol Ther Methods Clin Dev, 12:19-31 (2018).
[cited by applicant]
Froelich, et al., “Targeted Gene Delivery to CD117-expressing Cells in vivo with Lentiviral Vectors Co-displaying Stem Cell Factor and a Fusogenic Molecule,”, Biotechnology and Bioengineering, 104(1):206-215 (2009).
[cited by applicant]
Funke, et al., Targeted Cell Entry of Lentiviral Vectors,: Mol Ther. I6(8):1427-36 (2008).
[cited by applicant]
Goyvaerts, C., et al., “Development of the Nanobody Display Technology to Target Lentiviral Vectors to Antigen-Presenting Cells,” Gene Therapy, 19:1133-1140 (2012).
[cited by applicant]
Grubaugh, et al., “Proteins as T Cell Antigens: Methods for High-throughput Identification,” Vaccine 31(37) (2013).
[cited by applicant]
Li et al, “T Cell Antigen Discovery via Trogocytosis,” Nature Methods, 16(2):183-90 (2019).
[cited by applicant]
Hastie, E, et al., “Understanding and Altering Cell Tropism of Vesicular Stomatitis Virus,” Virus Res. 176(1-2):16-32 (2013).
[cited by applicant]
He, et al., “Can Immunotherapy Reinforce Chemotherapy Efficacy? A New Perspective on Colorectal Cancer Treatment,” Front. Immunol. 14:1237764 (2023).
[cited by applicant]
Höfig, I., et al., “Systematic Improvement of Lentivirus Transduction Protocols by Antibody Fragments Fused to VSV-G as Envelope Glycoprotein,” Biomaterials, 35(13):4204-12 (2014).
[cited by applicant]
Humes, D., “The TOP Vector: a New High-titer Lentiviral Construct for Delivery of sgRNAs and Transgenes to Primary T Cells,” Molecular Therapy Methods & Clinical Development, 20:30-38 (2021).
[cited by applicant]
Joglekar, et al., “T Cell Antigen Discovery via Signaling and Antigen-presenting Bifunctional Receptors,” Nature Methods, 16(2):191-8 (2019).
[cited by applicant]
Kameyama, Y., et al., “Antibody-dependent Gene Transduction using Gammaretroviral and Lentiviral Vectors Pseudotyped with Chimeric Vesicular Stomatitis Virus Glycoprotein,” J Viral Methods, 153(1 ):49-54 (2008).
[cited by applicant]
Karlin, et al., “Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences,” Proc Natl Acad Sci US A, 90(12):5873-7 (1993).
[cited by applicant]
Karlin, et al., “Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes,” Proc Natl Acad Sci US A., 87(6):2264-8 (1998).
[cited by applicant]
Kussie, P., et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” J Immunol, 152(1):146-52. (1994).
[cited by applicant]
Labbe, R., et al., “Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives,” Viruses 13(1528): 1-22 (2021).
[cited by applicant]
Milani, M., et al., “Genome Editing for Scalable Production of Alloantigen-free Lentiviral Vectors for in vivo Gene Therapy,” EMBO Mol Med, 9(11):1558-1573 (2017).
[cited by applicant]
Nikolic, J., et al., “Structural Basis for the Recognition of LDL-Receptor Family Members by VSV Glycoprotein,” Nature Communications, 9(1029):1-12 (2018).
[cited by applicant]
Ou, W, et al., “Specific Targeting of Human Interleukin (IL)-13 Receptor A2-positive Cells with Lentiviral Vectors Displaying IL-13,” Hum Gene Ther Methods, 2:137-47, (2012).
[cited by applicant]
Peach, et al., “Both Extracellular Immunoglobin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28, ”J. Biol Chem, 270(36):21181-21187 (1995).
[cited by applicant]
Roche, et al., “Crystal Structure of the Low-pH Form of the Vesicular Stomatitis Virus Glycoprotein,” G. Science, 313: 187-191 (2006).
[cited by applicant]
Roche, et al., “Structure of the Prefusion Form of the Vesicular Stomatitis Virus Glycoprotein G,” Science 315: 843-848 (2007).
[cited by applicant]
Schamback, A., et al., “Biosafety Features of Lentiviral Vectors,” Human Gene Therapy, 24:132-142 (2013).
[cited by applicant]
Sela-Culang, I., et al., “The Structural Basis of Antibody-Antigen Recognition,” Front Immunol, 4:302 (2013).
[cited by applicant]
Sevier, CS, et al., “Efficient Export of the Vesicular Stomatitis Virus G Protein from the Endoplasmic Reticulum Requires a Signal in the Cytoplasmic Tail that Includes both Tyrosine-based and Di-acidic Motifs,” Mol Bio…
[cited by applicant]
Sirin, S., et al., “AB-Bind: Antibody Binding Mutational Database for Computational Affinity Predictions,” Protein Sci, 25(2):393-409 (2015).
[cited by applicant]
Taube, et al., “Lentivirus Display: Stable Expression of Human Antibodies on the Surface of Human Cells and Virus Particles,” PLoS One, 3(9):e3181 (2008).
[cited by applicant]
Urban, et al., “Retroviral Display in Gene Therapy, Protein Engineering, and Vaccine Development,” ACS Chem Biol., 6(1):61-74(2011).
[cited by applicant]
Urban, et al., “Selection of Functional Human Antibodies from Retroviral Display Libraries,” Nucleic Acids Res., 33(4):e35 (2005).
[cited by applicant]
Beilstein, et al., “Identification of a pH-Sensitive Switch in VSV-G and a Crystal Structure of the G Pre-fusion State Highlight the VSV-G Structural Transition Pathway,” Cell Reports, 32, 108042, 2020.
[cited by applicant]
Bjorkman, et al., “Mutations That Affect Ligand Binding to the
[cited by applicant]
Bortoletto, et al., “Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells,” Eur. J. Immunol., 32:3102-3107, 2002.
[cited by applicant]
Knopp, et al., “Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout,” Molecular Therapy: Nucleic Acids, vol. 13, Dec. 2018.
[cited by applicant]
Lombardo, et al., “Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery,” Nature Biotechnology, vol. 25(11), Nov. 2007.
[cited by applicant]
Nikolic, et al., “Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein,” Nature Communications, 9:1029, 2018.
[cited by applicant]
Roche, et al., “Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited,” Cell. Mol. Life Sci., 65, 1716-1728, 2008.
[cited by applicant]
Baroja, et al., “Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation,” Journal of Immunology, 162(4):2016-23, 1999.
[cited by applicant]
Strausberg, et al., CD8a molecule [
[cited by applicant]
Brown, et al., “A Receptor Mediated Pathway for Cholesterol Homeostasis,” Science, vol. 232, p. 34-47, Apr. 4, 1986.
[cited by applicant]
Fernandez, et al., “Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease,” Journal of Virology, vol. 76, No. 2, p. 895-904, Jan. 2002.
[cited by applicant]
Goyvaerts, et al., “Targeting of Human Antigen-Presenting Cell Subsets,” Journal of Virology, 87(20):11304-11308, 2013.
[cited by applicant]
Harper, et al., “Purification of proteins fused to glutathione S-tranferase,” Methods Mol Biol.; 681: 259-280, 2011.
[cited by applicant]
Hastie, et al., “Oncolytic Vesicular Stomatitis Virus in an Immunocompetent Model of MUC1-Positive or MUC1-Null Pancreatic Ductal Adenocarcinoma,” Journal of Virology, p. 10283-10294, vol. 87, No. 18, Sep. 2013.
[cited by applicant]
Ho, et al., “Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling,” Cell, 168(6):1041-1052, 2017.
[cited by applicant]
Messer, et al., “Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders,” Neurobiology of Disease 134, 104619, 2020.
[cited by applicant]
Rose, et al., “Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1,” Journal o…
[cited by applicant]
Baquero, et al., “Recent mechanistic and structural insights on class III viral fusion glycoproteins,” Current Opinion on Structural Biology, 33:52-60, 2015.
[cited by applicant]
Beglova, et al., “The LDL receptor: how acid pulls the trigger,” Trends in Biochemical Sciences, 30(6), 2005.
[cited by applicant]
Buchholz, et al., “Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery,” Trends in Biotechnology, 33:12, 2015.
[cited by applicant]
Hwang, et al., “Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors,” Gene Therapy, 2013 with supplementary data.
[cited by applicant]
Joglekar, et al., “Pseudotyped Lentiviral Vectors: One Vector, Many Guises,” Human Gene Therapy Methods, 28(6), 2017.
[cited by applicant]
Lillis, et al., “LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies,” Physiol. Rev., vol. 88, 2008.
[cited by applicant]
Rucker, et al., “pH-dependent molecular dynamics of vesicular stomatitis virus glycoprotein G,” Proteins, 80:2601-2613, 2012 with supplementary data.
[cited by applicant]
WO 2010/040023 figures as filed as cited in EP Opposition for EP Application No. 18773448.8 dated May 14, 2025.
[cited by applicant]
Burt, et al., “Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies,” Human Vaccines & Immunotherapeutics, vol. 15(3), pp. 594-602, 2019.
[cited by applicant]
Lanzavecchia, et al., “The use of hybrid hybridomas to target human cytotoxic T lymphocytes,” Eur. J. Immunol., 17:105-111, 1987.
[cited by applicant]